Keywords: حداکثر دوز قابل تحمل; Ara-C; cytarabine; LA; lauric acid; LA-Ara; conjugation of cytarabine with lauric acid; LA-Ara NFs; LA-Ara nanofibers; AML; acute myeloid leukaemia; ALL; acute lymphoblastic leukaemia; lg P; oil/water partition coefficient; Ara-CTP; cytarbine triphosphate
مقالات ISI حداکثر دوز قابل تحمل (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: حداکثر دوز قابل تحمل; Acute inhalation studies; 3Rs; Evident toxicity; Fixed concentration procedure (FCP); Refinement; Regulatory toxicology; TG403; TG436; TG433; ATC; acute toxic class; CI; confidence interval; FCP; fixed concentration procedure; GHS; globally harmonised sys
Keywords: حداکثر دوز قابل تحمل; Anti-tumor immunity; Immune suppression; Immune memory; Drug development; Anti-cancer drug scheduling; DC; dendritic cell; ICD; immunogenic cell death; IFN; interferon; MEDIC; medium-dose intermittent chemotherapy; MTD; maximum tolerated dose; NK; natural
Keywords: حداکثر دوز قابل تحمل; 2-Ethylhexyl acrylate; Nongenotoxic irritant; Dermal carcinogenesis; C3H/HeJ mouse; Maximum tolerated dose; Strain selection;
Keywords: حداکثر دوز قابل تحمل; Arg-Gly-Asp; Arginylglycylaspartic acid; FDA; Food and Drug Administration; DNA; Deoxyribonucleic acid; NCI; National Cancer Institute; SCLC; Small cell lung cancers; NSCLC; Non-small cell lung cancers; 5-FU; 5-Fluorouracil; OTCs; Organic cationic transpo
Keywords: حداکثر دوز قابل تحمل; AM; alveolar macrophage; cAM; alveolar macrophage count (= TCC x AM); cPMN; polymorphonuclear neutrophil count (TCC x PMN); BAL; bronchoalveolar lavage; BET; Brunauer-Emmett-Teller; BMCL; benchmark concentration lower confidence limit; GSD; geometric stan
Keywords: حداکثر دوز قابل تحمل; Aβ1-42; 42-amino acid-long Aβ peptide; AD; Alzheimer's disease; ADAPT; Alzheimer's Disease Anti-Inflammatory Prevention Trial; ADAS-Cog; Alzheimer's Disease Assessment Scale-Cognitive Subscale; ADCS-ADL; Alzheimer's Disease Cooperative Study Activ
Keywords: حداکثر دوز قابل تحمل; 11BHSD; 11β-hydroxysteroid dehydrogenase; ACTH; adrenocorticotropic hormone; AE; adverse event; ALT; alanine aminotransferase; AUC; area under the curve; BMI; body mass index; CBG; cortisol binding globulin; CL/F; apparent total clearance of the drug fro
Keywords: حداکثر دوز قابل تحمل; Combination chemotherapy; Lung cancer; Mathematical modeling and computational simulation; Gemcitabine and cisplatin; Pharmacokinetics and pharmacodynamics; 2D; Two-dimensional; AUC; Area-under-the-curve; CDDP; Cisplatin (cis-diamminedichloroplatinum(II))
Keywords: حداکثر دوز قابل تحمل; AE; Adverse event; BIPN; Bortezomib-induced peripheral neuropathy; C-L; Caspase-like; CFZ; Carfilzomib; ChT-L; Chymotrypsin-like action; IRd; Ixazomib, lenalidomide, and dexamethasone; LG; Leaving group; MM; Multiple myeloma; MTD; Maximum tolerated dose;
Keywords: حداکثر دوز قابل تحمل; Endocrine disruption; Endocrine system; Systemic toxicity; Stress; Weight of evidence; Endocrine screening; Maximum tolerated dose;
Keywords: حداکثر دوز قابل تحمل; 56MESS; (1S2S-diaminocyclohexane)platinum(II)] dichloride; AIBN; 2,2â²-azobisisobutyronitrile; Apt; aptamer; AUC; area under curve; BBR3464; (trans,trans,trans)-bis-mu-(hexane-16-diamine)-mu-[diammineplatinum(II)]bis[diammine(chloro)platinum(II)] tetrani
Keywords: حداکثر دوز قابل تحمل; Maximum tolerated dose; Chronic toxicity; Carcinogenicity; Toxicokinetics; Gender difference; ADME; absorption, distribution, metabolism, and excretion; AUCs; areas under the curve; Cmax; maximum concentration; KMD; kinetically-derived maximum dose; MTD;
Keywords: حداکثر دوز قابل تحمل; Dose-limiting toxicity; Recommended phase II dose; Maximum tolerated dose; Dose-finding clinical trials; Early drug development; Paediatrics; Oncology;
Keywords: حداکثر دوز قابل تحمل; Dosing schedule; Liposomes; Maximum tolerated dose; Metronomic chemotherapy; Nanoparticles; Tumor priming;
Keywords: حداکثر دوز قابل تحمل; AE; adverse event; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; EGFR; epidermal growth factor receptor; FAK; focal adhesion kinase; IGFR; insulin growth factor receptor; MPM; malignant pleural mesothelioma; MTD; maximum tolerated dose; mTOR; mamma
Keywords: حداکثر دوز قابل تحمل; VEGF; Vascular Endothelial Growth Factor; MMP; Matrixmetalloproteinases; uPAR; UrokinasePlasminogen Activator Receptor; Ang-1; Angiotensin-1; TGF-β; Transforming Growth Factor-β; VEGFR; Vascular Endothelial Growth Factor Receptor; TKI; Tyrosine Kinase I
Keywords: حداکثر دوز قابل تحمل; HU; Hydroxyurea; MTD; Maximum Tolerated Dose; α-SCA; SCA with co-inherited α-thalassemia trait; HbF; Fetal Hemoglobin; SCA; Sickle Cell Anemia; Sickle cell anemia; Hydroxyurea; Alpha thalassemia;
Keywords: حداکثر دوز قابل تحمل; Hydroxyurea (HU); Sickle cell anemia (SCA); Pharmacometrics; D-optimal design; Bayesian individualized dosing; SCA; sickle cell anemia; MTD; maximum tolerated dose; PK; pharmacokinetics; PD; pharmacodynamics; AUC; area under the concentration-time curve;
Keywords: حداکثر دوز قابل تحمل; Phase I clinical trial; Dose-finding studies; Maximum tolerated dose; Optimal design;
Keywords: حداکثر دوز قابل تحمل; MN; micronucleus; CA; chromosomal aberrations; CBMN; cytokinesis-block micronucleus assay; GSH; glutathione; IARC; International Agency for Research on Cancer; i.p.; intraperitonelly; LOEL; lowest observed effect level; MTD; maximum tolerated dose; NOEL;
Keywords: حداکثر دوز قابل تحمل; ADH; adipic acid dihydrazide; AUNPs; gold nanoparticles; BA; butyric acid; CDDP; cisplatin; CHI; chitosane; CNTs; carbon nanotubes; CPT; camptothecin; CSCs; cancer stem cells; DiPhPE; diphytanoyl-sn-glycero-3-glycerophosphatidyl ethanolamine; DL; drug loa
Keywords: حداکثر دوز قابل تحمل; AE; adverse event; AED; antiepileptic drug; BMI; body mass index; CP; complex partial seizure; DB; double blind; EMA; European Medicines Agency; FDA; US Food and Drug Administration; ITT; intent to treat; MTD; maximum tolerated dose; PBO; placebo; PER; pe
Keywords: حداکثر دوز قابل تحمل; Genotoxicity; Cobalt compounds; Overall assessment; 2-AA; 2-aminoanthracene; 2NF; 2-nitrofluorene; 4-NOPD; nitro-o-phenylenediamine; 6Â TG; 6-thioguanine; 8-OH-dG; 8-hydroxy-2-deoxyguanosine; 9AA; 9-aminoacridine; AAF; artificial alveolar fluid; B[a]P; be
Keywords: حداکثر دوز قابل تحمل; Dose–response relationship; Drug toxicity; Maximum tolerated dose; Phase I clinical trials
Keywords: حداکثر دوز قابل تحمل; Allergen-specific IgE; allergen-specific IgG4; allergy immunotherapy; combined score; ragweed; specific immunotherapy; sublingual immunotherapy; AE; Adverse event; ANCOVA; Analysis of covariance; ARC; Allergic rhinoconjunctivitis; DSS; Daily symptom score
Keywords: حداکثر دوز قابل تحمل; Graphene nanoplatelets; Dextran; Toxicity; Dose range; Biodistribution; Maximum tolerated dose;
Keywords: حداکثر دوز قابل تحمل; log P; liposomes; albumin; micelles; nanoparticles; formulation vehicles; formulation; lipoproteins; pharmacokinetics; physicochemical; ATC; anatomical therapeutic chemical; DDS; drug delivery system; MPS; mononuclear phagocyte system; HSA; human serum al
Keywords: حداکثر دوز قابل تحمل; Microalgae; Fermentation; Oleic-rich oil; Genotoxic; Mutagenic; Subchronic toxicity; 2-AA; 2-aminoanthracene; AAALAC; Association for Assessment and Accreditation of Laboratory Animal Care International; ANOVA; Analysis of Variance; AOAC; Association of A
Keywords: حداکثر دوز قابل تحمل; CPA; cyclophosphamide; MTD; maximum tolerated dose; NK; natural killer; Prf1; perforin-1;
Keywords: حداکثر دوز قابل تحمل; B2M; beta 2 microglobulin; CAR; cyclophophamide, alvocidib, rituximab; CDK; cyclin-dependent kinase; CLL; chronic lymphocytic leukemia; CR; complete response; CRS; cytokine release syndrome; DLT; dose limiting toxicity; ECOG; Eastern Cooperative Oncology
Keywords: حداکثر دوز قابل تحمل; Histopathology; Minocycline hydrochloride; Maximum tolerated dose; Chitosan nanoparticles;
Keywords: حداکثر دوز قابل تحمل; Chitosan; Elevated plus maze; Maximum tolerated dose; Morris water maze; Optimization; Rivastigmine tartrate;
Keywords: حداکثر دوز قابل تحمل; 3Rs; replacement, reduction, refinement; NC3Rs; National centre for the replacement, refinement and reduction of animals in research; BWL; body weight loss; MTD; maximum tolerated dose; NHPs; non-human primates; 3Rs; Body weight loss (BWL); Maximum tolera
Keywords: حداکثر دوز قابل تحمل; ADRs; adverse drug reactions; AEs; adverse effects; BPM; breaths per minute; DRF; dose range finding; GI; gastrointestinal; ICH; International Conference on Harmonisation; MTD; maximum tolerated dose; MV; minute volume; NSAID; non-steroidal anti-inflammat
The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment
Keywords: حداکثر دوز قابل تحمل; Injectable hydrogel; Maximum tolerated dose; Localized drug delivery; Cancer therapy;
The role of ethyl acrylate induced GSH depletion in the rodent forestomach and its impact on MTD and in vivo genotoxicity in developing an adverse outcome pathway (AOP)
Keywords: حداکثر دوز قابل تحمل; GSH depletion; Transgenic mouse assay; Ethyl acrylate; CAS# 140-88-5; Rodent forestomach tumors; gpt delta mouse; Maximum tolerated dose;
dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials
Keywords: حداکثر دوز قابل تحمل; Dose-finding; Maximum tolerated dose; Pharmacokinetics; Phase I clinical trials; R package;
Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer
Keywords: حداکثر دوز قابل تحمل; c-MET; Colorectal cancer (CRC); Hepatocyte growth factor; Maximum tolerated dose; SAIT301;
A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer
Keywords: حداکثر دوز قابل تحمل; 7-AAD; 7-amino-actinomycin D; ABC; ATP-binding cassette; AEC; 3-amino-9-ethyl carbazole; ATD; acute toxicity determination; Atg5; autophagy protein 5; ATP; adenosine-5â²-triphosphate; BCL-2; B-cell lymphoma 2; Bip/GRP78; binding immunoglobulin protein/78
Toxicological study of a new doxorubicin-loaded pH-sensitive liposome: A preclinical approach
Keywords: حداکثر دوز قابل تحمل; Doxorubicin; pH-sensitive liposomes; Acute toxicity; Cardiotoxicity; Electrocardiogram; ALT; Alanine Aminotransferase; ANOVA; Analysis of Variance; AST; Aspartate Aminotransferase; CHEMS; Cholesteryl Hemisuccinate; CHOL; Cholesterol; CK-MB; Creatine Kinas
A transcriptomic analysis of black cohosh: Actein alters cholesterol biosynthesis pathways and synergizes with simvastatin
Keywords: حداکثر دوز قابل تحمل; Actein; Black cohosh; Microarrays; Ranunculaceae; Simvastatin; Triterpene glycoside; CI; Combination Index; CYP; Cytochrome P450; DMSO; dimethylsulfoxide; DMEM; Dulbecco's Modified Eagle's medium; ERK; Extracellular signal related kinase; EtOH; ethanol; F
Bispecific antibodies for cancer therapy: A review
Keywords: حداکثر دوز قابل تحمل; ADCC; antibody-dependent cell-mediated cytotoxicity; AE; adverse events; ALL; acute lymphoblastic leukemia; ALP; alkaline phosphatase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; B-ALL; B-cell acute lymphoblastic leukemia; BiTES; Bi-sp
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Keywords: حداکثر دوز قابل تحمل; Akt; oncogene in the transforming retrovirus, AKT8; AP-1; activator protein 1; ARAF; v-raf murine sarcoma 3611 viral oncogene homologue; ASK1; apoptosis signal-regulating kinase 1; BCL2; B-cell lymphoma 2; BCL-XL; B-cell lymphoma extra large; BRAF; v-raf
Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic
Keywords: حداکثر دوز قابل تحمل; ALL; Acute lymphoblastic leukemia; AML; Acute myeloid leukemia; AUC; Area under the curve; AZA; 5-azacytidine; 5-aza-CdR; 2â²-deoxy-5-azacytidine; 5-aza-CR; 5-azacytidine; AZN; Azanucleosides; BED; Biologically effective dose; BSC; Best supportive care;
A 28-day oral toxicology study of an aqueous extract of Polypodium leucotomos (Fernblock®)
Keywords: حداکثر دوز قابل تحمل; A/G ratio; albumin to globulin ratio; ANOVA; analysis of variance; BALT; bronchus associated lymphoid tissue; FOB; functional observation battery; MTD; maximum tolerated dose; NOAEL; no observed adverse effect level; OECD; Organisation for Economic Cooper
Acute and subchronic toxicity studies of seabuckthorn (Hippophae rhamnoides L.) oil in rodents
Keywords: حداکثر دوز قابل تحمل; Hippophae rhamnoides; Seabuckthorn oil; Subchronic toxicity; Safety; NOAEL; no-observed-adverse-effect level; SD; Sprague-Dawley; SPF; specific pathogen free; EDTA; ethylene-diamine-tetra-acetic acid; MTD; maximum tolerated dose; HPLC; high performance li
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
Keywords: حداکثر دوز قابل تحمل; AE; Adverse Event; α-MSH; alpha-Melanocyte Stimulating Hormone; ADC; Antibody-Drug Conjugate; ASPS; Alveolar Soft Part Sarcoma; ASPSCR1; Alveolar Soft Part Sarcoma Chromosome Region Candidate 1; BMP-2; Bone Morphogenetic Protein-2; BRK; Breast Tumor Kina
Systematic comparison of the statistical operating characteristics of various Phase I oncology designs
Keywords: حداکثر دوز قابل تحمل; Phase 1 designs; Oncology; Dose finding; Rule-based designs; Model-based designs; Accuracy of MTD selection; DLT; dose limiting toxicity; MTD; maximum tolerated dose; mTPI design; modified toxicity probability interval design; TEQR design; toxicity equiva
EMICORON: A multi-targeting G4 ligand with a promising preclinical profile
Keywords: حداکثر دوز قابل تحمل; G4; G-quadruplex; TIFs; telomere-dysfunction induced foci; CRC; colorectal cancer; MTD; maximum tolerated dose; PDX; patient-derived xenografts; GEMM; genetically engineered mouse models; CI; combination index; MTS; multicellular tumor spheroids; TWI; tum